Patent application number | Description | Published |
20090162390 | Molecular Scaffolds for HIV-1 Immunogens - Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These chimeric polypeptides behave as molecular scaffolds which are capable of presenting the various heterologous HIV-1 epitopes. The invention demonstrates that a heterologous epitope recognized by the HIV-1 neutralizing antibody can be more fully exposed to neutralizing antibodies when presented within the backbone of the chimeric polypeptide than when the epitope is presented within the context of an HIV-1 backbone. Polynucleotides encoding these chimeric polypeptides are also provided. Immunogenic compositions are provided which comprise a chimeric polypeptide having at least one heterologous epitope that interacts with an HIV-1 neutralizing antibody. Immuno genie compositions comprising chimeric polynucleotides encoding the chimeric polypeptides of the invention are also provided. Vaccines comprising such immunogenic compositions are also provided. Further provided are methods which employ the immunogenic compositions of the invention. Such methods include, for example, methods for eliciting an immune response in a subject, methods for generating antibodies specific for the chimeric polypeptide or the chimeric polypeptide, and methods for inhibiting or preventing infection by HIV-1 in a subject. | 06-25-2009 |
20090198042 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 08-06-2009 |
20090324631 | Polyvalent Vaccine - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 12-31-2009 |
20100104596 | ACUTTE TRANSMITTED HIV ENVELOPE SIGNATURES - The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to a method of inducing an immune response to HIV in a patient and to immunogens suitable for use in such a method. The invention also relates to diagnostic test kits and methods of using same. | 04-29-2010 |
20110150915 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 06-23-2011 |
20110301328 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 12-08-2011 |
20120087938 | Consensus/ancestral immunogens - The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens. | 04-12-2012 |
20120121631 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 05-17-2012 |
20120231028 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 09-13-2012 |
20130177583 | MOLECULAR CLONE OF HIV-1 - The present invention relates, in general, to HIV-1 and, in particular, to a molecular clone of HIV-1. The invention further relates to methods of inducing an immune response to HIV-1 in a patient and to immunogens suitable for use in such methods. The invention also relates to anti-HIV-1 antibodies and to methods of using same to prevent or treat HIV-infection. | 07-11-2013 |
20140023683 | IDENTIFICATION OF TRANSMITTED HEPATITIS C VIRUS (HCV) GENOMES BY SINGLE GENOME AMPLIFICATION - This invention provides methods for identifying HCV genomes and more specifically, methods for identifying nucleotide sequence of viral structural proteins at the time of HCV viral transmission. The method of the invention utilizes single genome amplification and sequencing of circulating virus as well as phylogenetic analysis of the resulting nucleotide sequence for identifying transmitted HCV genomes. Also provided are HCV genomes and corresponding nucleotide sequence for transmitted and circulating HCV virus. The invention further provides methods of administering a vaccine comprising one or more identified transmitted HCV sequences. | 01-23-2014 |